Prime Medicine, Inc.

NasdaqGM PRME

Prime Medicine, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD -2.01

Prime Medicine, Inc. EPS (Diluted) is USD -2.01 for the Trailing 12 Months (TTM) ending September 30, 2024, a -0.00% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Prime Medicine, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -2.01, a 11.06% change year over year.
Prime Medicine, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.26.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqGM: PRME

Prime Medicine, Inc.

CEO	Dr. Keith Michael Gottesdiener M.D., Ph.D.
IPO Date	Oct. 20, 2022
Location	United States
Headquarters	21 Erie Street
Employees	234
Sector	Healthcare
Industries Biotechnology

Description

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years